Table 3 Cox proportional hazards regression analysis for the risk of herpes zoster.

Gender

 Female

613

87,015

7.04

720

88,889

8.10

1.15

(1.03, 1.28)*

0.01

1.12

(1.00, 1.24)*

0.04

 Male

336

55,646

6.04

395

57,921

6.82

1.11

(0.96, 1.28)

0.16

1.06

(0.91, 1.22)

0.46

Age, year

 20–29

91

27,166

3.35

89

27,168

3.28

0.99

(0.74, 1.33)

0.95

0.98

(0.73, 1.31)

0.89

 30–39

137

37,438

3.66

181

37,664

4.81

1.33

(1.06, 1.66)*

0.01

1.33

(1.06, 1.66)*

0.01

 40–49

205

34,194

6.00

248

35,003

7.09

1.17

(0.97, 1.41)

0.09

1.18

(0.98, 1.42)

0.08

 ≥ 50

516

43,864

11.76

597

46,975

12.71

1.04

(0.93, 1.17)

0.48

1.03

(0.91, 1.16)

0.65

Comorbidities

 Without comorbidities

496

96,622

5.13

595

97,677

6.09

1.19

(1.06, 1.34)**

0.00

1.18

(1.05, 1.33)**

0.01

 With comorbidities^a

453

46,040

9.84

520

49,133

10.58

1.04

(0.92, 1.18)

0.54

1.01

(0.89, 1.14)

0.90

  DM

   No

630

109,665

5.74

747

111,575

6.70

1.16

(1.05, 1.29)**

0.00

1.14

(1.02, 1.26)*

0.02

   Yes

319

32,996

9.67

368

35,235

10.44

1.05

(0.90, 1.22)

0.56

1.01

(0.87, 1.17)

0.91

  CKD

   No

937

141,121

6.64

1090

144,877

7.52

1.12

(1.03, 1.23)**

0.01

1.09

(1.00, 1.19)

0.05

   Yes

12

1540

7.79

25

1932

12.94

1.51

(0.74, 3.07)

0.26

1.44

(0.7, 2.95)

0.32

  CAD

   No

730

122,296

5.97

828

124,960

6.63

1.11

(1.00, 1.23)*

0.04

1.09

(0.98, 1.20)

0.11

   Yes

219

20,366

10.75

287

21,850

13.14

1.16

(0.97, 1.38)

0.11

1.12

(0.94, 1.34)

0.19

  Cancer

   No

914

140,426

6.51

1086

143,974

7.54

1.15

(1.05, 1.26)**

0.00

1.11

(1.02, 1.22)*

0.02

   Yes

35

2236

15.65

29

2836

10.22

0.59

(0.36, 0.97)*

0.04

0.55

(0.33, 0.90)*

0.02